Drug Trial Radar · NCT05546476
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
187
Actual
Start
Nov 21, 2022
Primary completion
Mar 13, 2024
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
Conditions
- Non-small Cell Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Loss of Appetite
- Fatigue
- Cachexia
Interventions
ponsegromabDrug
Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
Placebo for ponsegromabDrug
Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change From Baseline in Body Weight at Week 12Time frame: Baseline, Week 12
Locations
78 sites in 11 countries. Site status is shown where the registry gives one.
CARTI Conway
Conway, Arkansas
CARTI Cancer Center
Little Rock, Arkansas
CARTI North Little Rock
North Little Rock, Arkansas
CARTI Stuttgart
Stuttgart, Arkansas
Pacific Cancer Medical Center INC
Anaheim, California
Beverly Hills Cancer Center
Beverly Hills, California
Emad Ibrahim,MD,INC.
Redlands, California
Providence Medical Foundation
Santa Rosa, California
IU Health Arnett Cancer Center
Lafayette, Indiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Tandem Clinical Research
Marrero, Louisiana
Bozeman Health Deaconess Hospital
Bozeman, Montana
Oregon Health and Science University: Center for Health and Healing 1
Portland, Oregon
Oregon Health and Science University: Center for Health and Healing 2
Portland, Oregon
Oregon Health and Science University
Portland, Oregon
The University of Texas MD Anderson Cancer Center
Houston, Texas
Carta - Clinical Associates in Research Therapeutics of America, LLC
San Antonio, Texas
Virginia Mason Medical Center
Seattle, Washington
Wenatchee Valley Hospital
Wenatchee, Washington
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Orange Hospital
Orange, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Western Health-Sunshine & Footscray Hospitals
St Albans, Victoria, Australia
Complex Oncology Center - Burgas
Burgas, Bulgaria
Specialized Hospital for Active Treatment of Oncology - Haskovo
Haskovo, Bulgaria
Complex Oncology Center - Ruse EOOD
Rousse, Bulgaria
Complex Oncology Center - Shumen
Shumen, Bulgaria
Multiprofile Hospital for Active Treatment Serdika EOOD
Sofia, Bulgaria
MHAT for Women's Health Nadezhda
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Sofiamed
Sofia, Bulgaria
Complex Oncology Center - Vratsa
Vratsa, Bulgaria
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CIUSSS- saguenay-Lac-Saint-Jean
Chicoutimi, Quebec, Canada
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski
Rimouski, Quebec, Canada
Peking University First Hospital
Beijing, Beijing Municipality, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.